Coherus Oncology, Inc. Share Price & Technical Analysis
CHRS · $1.64 (+1.86%)
Healthcare / Biotechnology
$1.64
+1.86%
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin …
Price chart
Seasonality
May has 0 positive and 5 negative years (last 5 years shown)
-11% return in May, -25% avg return in past 3 year May month.
39% return in 2026, -13% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 57% | -19% | 6% | 6% | -11% | – | – | – | – | – | – | – | 39% |
| 25 | -14% | 0% | -27% | 25% | -20% | -12% | 29% | 33% | 45% | 6% | -18% | 8% | 55% |
| 24 | -33% | 5% | 4% | -17% | -10% | -6% | -12% | -7% | -23% | -30% | 71% | 17% | -40% |
| 23 | 6% | -19% | 0% | 6% | -45% | 2% | 9% | 10% | -31% | -13% | -36% | 57% | -54% |
| 22 | -23% | -5% | 10% | -30% | -18% | -1% | 18% | 32% | -14% | -11% | -22% | 14% | -50% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$248.07M
P/E ratio
—
52W high
$2.62
52W low
$0.71
Volume
9,04,469
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Coherus Oncology, Inc. share price today?
- Coherus Oncology, Inc. (CHRS) last traded around $1.64 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CHRS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CHRS. Download the app for real-time alerts.
- How can I analyze Coherus Oncology, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.